Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI RAPID trial of positron emission tomography–directed therapy for early-stage Hodgkin lymphoma

Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI RAPID trial of positron emission tomography–directed therapy for early-stage Hodgkin lymphoma

<p><strong>Purpose</strong></p> The contemporary management of early-stage Hodgkin lymphoma (ES-HL) involves balancing the risk of late adverse effects of radiotherapy against the increased risk of relapse if radiotherapy is omitted. This study provides information on the ris...

Full description

Bibliographic Details
Main Authors:	Cutter, DJ, Ramroth, J, Diez, P, Buckle, A, Ntentas, G, Popova, B, Clifton-Hadley, L, Hoskin, PJ, Darby, SC, Radford, J, Illidge, T
Format:	Journal article
Language:	English
Published:	American Society of Clinical Oncology 2021

Similar Items

Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: Modelling life expectancy using radiation dosimetry
by: Jones, DA, et al.
Published: (2021)

P077: Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans
by: Rebecca Shakir, et al.
Published: (2022-10-01)

T022: Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
by: Rebecca Shakir, et al.
Published: (2022-10-01)

Interim results of a UK NCRI randomised trial comparing involved field radiotherapy with no further treatment after 3 cycles ABVD and a negative PET scan in clinical stages IA/IIA Hodgkin lymphoma
by: Radford, J, et al.
Published: (2007)

Individualised estimation of quality-adjusted survival benefit and cost-effectiveness of proton beam therapy in intermediate-stage Hodgkin lymphoma
by: Jones, DA, et al.
Published: (2023)

Clinical intensity modulated proton therapy for Hodgkin lymphoma: which patients benefit the most?
by: Ntentas, G, et al.
Published: (2019)

P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
by: David Jones, et al.
Published: (2022-10-01)

Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
by: Houlihan, OA, et al.
Published: (2022)

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines
by: van Nimwegen, F, et al.
Published: (2017)

P073: Increased risk of colorectal cancer following treatment for Hodgkin lymphoma
by: Yvonne M.G. Geurts, et al.
Published: (2022-10-01)

Determination of Hodgkin and non-Hodgkin lymphoma stage with combined positron-emission and computed tomography
by: I. V. Boikov, et al.
Published: (2011-12-01)

Cancer Informatics in the U.K.: The NCRI Informatics Initiative
by: Fiona Reddington, et al.
Published: (2006-01-01)

Cancer Informatics in the U.K.: The NCRI Informatics Initiative
by: Fiona Reddington, et al.
Published: (2006-01-01)

T013 (0095) MAXIMUM TUMOUR DIMENSION AT BASELINE IS ASSOCIATED WITH EVENT-FREE SURVIVAL IN PET NEGATIVE PATIENTS WITH STAGE IA/IIA HODGKIN LYMPHOMA IN THE UK NCRI RAPID TRIAL
Published: (2018-10-01)

Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma.
by: Hoskin, P, et al.
Published: (2005)

Risk of valvular heart disease after treatment for Hodgkin lymphoma
by: Cutter, D, et al.
Published: (2015)

Individualising the use of radiotherapy for the treatment of people with Hodgkin lymphoma
by: Shakir, R
Published: (2022)

THE EVOLVING ROLE OF RADIOTHERAPY IN EARLY STAGE HODGKIN’S LYMPHOMA
by: Umberto Ricardi, et al.
Published: (2014-05-01)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
by: Elizabeth H. Phillips, et al.
Published: (2020-07-01)

Long-term risk of ischemic heart disease following Hodgkin lymphoma treatment
by: Van Nimwegen, F, et al.
Published: (2013)

Fluorodeoxyglucose-positron emission tomography staging can replace bone marrow biopsy in Hodgkin's lymphoma. Results from Brazilian Hodgkin's Lymphoma Study Group
by: Juliano Júlio Cerci, et al.
Published: (2018-07-01)

A multicentre NCRI phase II study of hypofractionated conformal radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer
by: Choudhury, A, et al.
Published: (2010)

Risks of heart disease after radiotherapy.
by: Cutter, D, et al.
Published: (2011)

PROGNOSTIC SIGNIFICANCE OF POSITRON EMISSION TOMOGRAPHY IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NON-HODGKIN’S LYMPHOMA
by: V. G. Potapenko, et al.
Published: (2017-01-01)

Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
by: Lapuz C, et al.
Published: (2018-04-01)

Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin’s lymphoma
by: Yu Ri Kim, et al.
Published: (2021-03-01)

Positron Emission Tomography/Computed Tomography False Positivity for Xanthogranulomatous Inflammation in an Adolescent with Hodgkin's Lymphoma
by: Jui-Ting Yu, et al.
Published: (2014-06-01)

The role of motion management and position verification in lymphoma radiotherapy
by: Aznar, M, et al.
Published: (2021)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
by: F. Kallel, et al.
Published: (2022-06-01)

Radiotherapy for Non-Hodgkin’s lymphoma with cardiac infiltration: A case report
by: Weifeng Wang, et al.
Published: (2023-10-01)

The effectiveness of chemo-radiotherapy programs of last generation in patients with hodgkin's lymphoma
by: E. A. Demina, et al.
Published: (2022-11-01)

P188 EFFECTS OF RADIOTHERAPY ON LARGE VESSELS IN HODGKIN LYMPHOMA SURVIVORS
by: Anna Paini, et al.
Published: (2017-12-01)

Application of conformal radiotherapy in treatment of non-Hodgkin head and neck lymphoma
by: Goran Marošević, et al.
Published: (2012-11-01)

NCRI CTRad workshop: translating novel discoveries to and from the clinic
by: Hak, CCW, et al.
Published: (2023)

18F-FDG positron emission tomography in the diagnosis and staging of marginal zone non-Hodgkin lymphomas
by: M. M. Khodzhibekova, et al.
Published: (2016-02-01)

Long-term hospitalisation rates among 5-year survivors of Hodgkin Lymphoma in adolescence or young adulthood - A nationwide cohort study.
by: Rugbjerg, K, et al.
Published: (2017)

Radiation dosimetry for studying the late effects of radiotherapy
by: Ntentas, G
Published: (2018)

Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin Lymphoma
by: van Nimwegen, F, et al.
Published: (2015)

Radiotherapy research priorities for the UK.
by: Maughan, T, et al.
Published: (2010)

Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?
by: De Sanctis Vitaliana, et al.
Published: (2012-08-01)